When discussing the role of GLP-1 receptor agonists in the regulation of pathways influencing prostate cancer carcinogenesis, it is worth mentioning dipeptidyl peptidase 4 (DPP-4), which also regulates the activity of the ERK1/2- and mTOR-dependent pathway. This evidence concerns the gene DPP4 and prostate carcinoma.